Grant Opportunities from Pfizer International LLC
Explore all the grants from the leading funding organizations of the world in a single place
Advancing Genomic Competence and Patient Centered Care in Metastatic Breast Cancer
Pfizer LLC offers grants to healthcare professionals to advance genomic competence and patient-centered communication in metastatic breast cancer management.
Published At
2026 Vac Eastern Cluster RSV Detection QI
Pfizer LLC offers grants up to 50,000 USD to healthcare institutions to optimize RSV diagnosis and improve detection pathways in adult patients across the Eastern Cluster.
Published At
Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality Improvement
Pfizer International LLC offers QI grants to Kazakhstan healthcare organizations to improve oncology data collection, molecular diagnostic integration, and precision care pathways.
Published At
Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing Equity
Pfizer International LLC offers grants to healthcare professionals in Australia to enhance knowledge in ulcerative colitis management, focusing on biomarkers and equity.
Published At
Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi Arabia
Pfizer offers research grants to Saudi Arabian institutions for studies on pediatric pneumococcal disease epidemiology and serotype distribution using surveillance methods.
Published At
2026 Hemophilia Fellowship – United States
Pfizer offers a $100,000 USD fellowship for US-based academic institutions to support hemophilia care through shared decision making, patient education, and multidisciplinary care.
Published At
Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia Areata
Pfizer Inc. invites proposals for educational programs on the mechanism of action of JAK3 and TEC family kinases in alopecia areata for dermatologists and healthcare professionals.
Published At
Developing Educational Initiatives for Implementation and Therapy Management of B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)
Pfizer offers grants up to $125,000 to US healthcare organizations to improve professional competency in managing BCMA BsAbs for Relapsed/Refractory Multiple Myeloma.
Published At
Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)
Pfizer Inc. offers a research grant for medical societies and professional organizations to develop a shared decision-making tool for patients with ATTR-CM.
Published At
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
Pfizer International LLC offers research grants to Spanish institutions for real-world evidence generation regarding elranatamab use in Relapsed/Refractory Multiple Myeloma.
Published At